Evidence map›Paper›PMID 42073483›Full record

ArticleLife (Basel, Switzerland)2026

Features of Cross-Seeding of Wild-Type Alpha-Synuclein and Its Mutant Form A53T Potentially Useful for the Development of Test Systems.

Kseniya Barinova, Sofiya Kudryavtseva, Lidia Kurochkina, Sergei Golyshev, Nataliya Kolotyeva, Sergei Illarioshkin, Michail Piradov, Vladimir Muronetz

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kseniya BarinovaBelozersky Research Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.
Sofiya KudryavtsevaBelozersky Research Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0001-7549-607X
Lidia KurochkinaBelozersky Research Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0002-1030-0037
Sergei GolyshevBelozersky Research Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0002-4877-1061
Nataliya KolotyevaRussian Center of Neurology and Neurosciences, Moscow 125367, Russia.ORCID 0000-0002-7853-6222
Sergei IllarioshkinRussian Center of Neurology and Neurosciences, Moscow 125367, Russia.
Michail PiradovRussian Center of Neurology and Neurosciences, Moscow 125367, Russia.
Vladimir MuronetzBelozersky Research Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2024-638
6 · The paper itself

Abstract

Since the features of cross-seeding of alpha-synuclein forms may affect the sensitivity and specificity of the test systems, we developed a modified approach to obtain alpha-synuclein amyloid seeds with particle sizes from 20 to 50 nm prepared from either the wild-type protein (α-synWT) or its more fibrillation-prone form A53T (α-synA53T). These seeds had optimal properties for subsequent initiation of fibrillation. Our data showed that the elevated efficiency of alpha-synuclein A53T monomer transformation was hardly affected by the type of used seeds, whereas the addition of the seeds obtained from the alpha-synuclein mutant form to wild-type protein monomers had a significantly smaller effect than α-synWT seeds. Transmission electron microscopy data revealed that in the presence of α-synWT seeds the wild-type alpha-synuclein formed long and wide fibrils, while the addition of α-synA53T seeds led to the formation of long, but thin fibrils. Since the lag period of α-synA53T monomer fibrillation was significantly reduced compared to the wild-type protein, the replacing of α-synWT with α-synA53T in current assay systems designed to detect aberrant forms of α-synuclein in biological fluid samples (e.g., RT-QuIC) could substantially cut the time of analysis. In the future, a set of alpha-synuclein mutant forms could be used for the differential diagnosis of synucleinopathies caused by the different mutations of this protein.

Indexed as

alpha-synucleinamyloid transformationcross-fibrillationneurodegenerative diseasesRT-QuICseeds

Identifiers

PMID42073483
PMCPMC13117027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.